Therefore, it was postulated, and shown in KRAS CRC cell line analysis, that concomitant EGFR and KRAS G12C blockade overcomes secondary resistance to anti-EGFR antibodies, increasing cell death rate (101). Here, KRAS is linked to colorectal carcinoma.